IDH1 Gene Function
Isocitrate Dehydrogenase (NADP+) 1
Overview
IDH1 normally produces α-ketoglutarate in the cytosol. Cancer-associated hotspot mutations create a neomorphic enzyme that produces D-2-hydroxyglutarate, altering dioxygenase activity, DNA methylation and cellular differentiation.
Molecular Mechanism
Detailed mechanism data is not yet available for IDH1.
Key Pathways
- ·Citrate metabolism
- ·2-hydroxyglutarate production
- ·DNA and histone demethylation
Disease Associations
- ·Diffuse glioma
- ·Acute myeloid leukaemia
- ·Chondrosarcoma
Research Activity
IDH1 is an actively studied target: about 50+ clinical trials that mention it are currently recruiting on ClinicalTrials.gov. Trial activity reflects research interest, not proven benefit — designs, endpoints and populations vary widely.
Track IDH1 trials
New and changed oncology trials, summarised in plain language each day.
Functional Partners
Common Questions About IDH1
What does IDH1 do?
IDH1 participates in Citrate metabolism, 2-hydroxyglutarate production, DNA and histone demethylation. IDH1 normally produces α-ketoglutarate in the cytosol. Cancer-associated hotspot mutations create a neomorphic enzyme that produces D-2-hydroxyglutarate, altering dioxygenase activity, DNA methylation and cellular differentiation.
Why is IDH1 relevant to cancer research?
Its reported relevance includes Diffuse glioma, Acute myeloid leukaemia, Chondrosarcoma. The exact alteration, assay and disease context determine what a result can support.